AstraZeneca PLC (LON:AZN)
13,284
+84 (0.64%)
Jun 16, 2026, 5:15 PM GMT
AstraZeneca Employees
AstraZeneca had 96,100 employees as of December 31, 2025. The number of employees increased by 1,800 or 1.91% compared to the previous year.
Employees
96,100
Change (1Y)
1,800
Growth (1Y)
1.91%
Revenue / Employee
476.28K GBP
Profits / Employee
81.87K GBP
Market Cap
206.03B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 96,100 | 1,800 | 1.91% |
| Dec 31, 2024 | 94,300 | 4,400 | 4.89% |
| Dec 31, 2023 | 89,900 | 6,400 | 7.66% |
| Dec 31, 2022 | 83,500 | 400 | 0.48% |
| Dec 31, 2021 | 83,100 | 7,000 | 9.20% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| GSK plc | 66,841 |
| Haleon | 24,535 |
| Spire Healthcare Group | 17,800 |
| Smith & Nephew | 16,988 |
| Convatec Group | 10,910 |
| Hikma Pharmaceuticals | 9,400 |
| CVS Group | 9,000 |
| Genus | 3,190 |
AstraZeneca News
- 1 day ago - AstraZeneca (AZN) Faces Changes in Medicare Drug Price Negotiation Framework - GuruFocus
- 1 day ago - AstraZeneca (AZN) Receives Priority Review for Ultomiris Treatment Application - GuruFocus
- 1 day ago - AstraZeneca’s sBLA for Ultomiris granted Priority Review by U.S. FDA - TheFly
- 3 days ago - Drugmakers race to find a place in the next wave of obesity drugs - CNBC
- 3 days ago - AstraZeneca : FDA Approves Truqap Combination For PTEN-Deficient Metastatic Prostate Cancer - Nasdaq
- 4 days ago - TRUQAP® (capivasertib) combination approved in the US as first and only targeted treatment for PTEN-deficient metastatic hormone-sensitive prostate cancer - Business Wire
- 4 days ago - TRUQAP (capivasertib) combination approved in the US as first and only targeted treatment for PTEN-deficient metastatic hormone-sensitive prostate cancer - Wallstreet:Online
- 4 days ago - AstraZeneca (AZN) Gains from New Diagnostic Test Approval - GuruFocus